What is Acadia Healthcare's operating income?

Acadia Healthcare's total operating income in 2025 was -$925.81 million, based on the following breakdown: Total Gross Profit: $1.49 billion Total Operating Expenses: $2.42 billion

Acadia Healthcare (ACHC) Financials

$30.83 +0.59 (+1.95%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$30.82 0.00 (-0.02%)

As of 08/14/2026 07:34 PM Eastern

Compare

Annual Income Statements for Acadia Healthcare

This table shows Acadia Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	113	6.14	200	-176	109	-672	191	273	-22	256	-1,103
Consolidated Net Income / (Loss)	111	4.18	200	-175	110	-669	196	280	-16	264	-1,092
Net Income / (Loss) Continuing Operations	111	4.18	200	57	53	143	208	280	-16	264	-1,092
Total Pre-Tax Income	165	33	237	67	78	184	276	374	-25	342	-1,066
Total Operating Income	271	214	413	252	266	309	360	422	50	458	-926
Total Gross Profit	821	1,269	1,300	774	901	935	1,071	1,217	1,356	1,463	1,492
Total Revenue	1,830	2,853	2,877	1,905	2,008	2,090	2,314	2,610	2,929	3,154	3,313
Operating Revenue	1,830	2,853	2,877	1,905	2,008	2,090	2,314	2,610	2,929	3,154	3,313
Total Cost of Revenue	1,009	1,584	1,577	1,131	1,107	1,155	1,244	1,393	1,572	1,691	1,821
Operating Cost of Revenue	974	1,542	1,536	1,131	1,107	1,155	1,244	1,393	1,572	1,691	1,821
Total Operating Expenses	549	1,055	887	522	635	626	711	795	1,306	1,005	2,418
Selling, General & Admin Expense	323	615	642	354	464	470	529	607	671	743	867
Depreciation Expense	64	135	143	80	88	95	107	118	132	150	189
Other Operating Expenses / (Income)	115	252	77	36	35	37	39	45	47	48	48
Impairment Charge	-	0.00	0.00	0.00	27	4.75	24	0.00	9.79	17	1,008
Restructuring Charge	37	48	24	30	21	12	13	24	62	47	164
Other Special Charges / (Income)	11	4.25	0.81	22	-	7.23	0.00	0.00	384	0.00	142
Total Other Income / (Expense), net	-107	-181	-176	-185	-187	-125	-84	-48	-76	-116	-140
Interest Expense	-	-	-	185	187	158	102	70	82	116	140
Interest & Investment Income	-107	-181	-176	-	0.00	33	18	21	6.42	0.00	0.00
Income Tax Expense	53	29	37	9.91	25	41	68	94	-9.70	77	26
Net Income / (Loss) Attributable to Noncontrolling Interest	-1.08	-1.97	-0.25	0.26	1.20	2.93	4.93	6.89	6.01	8.87	11
Basic Earnings per Share	$1.65	$0.07	$2.30	($2.01)	$1.24	($7.65)	$2.15	$3.05	($0.24)	$2.79	($12.16)
Weighted Average Basic Shares Outstanding	68.09M	85.70M	86.95M	87.29M	87.61M	87.88M	88.77M	89.68M	90.95M	91.62M	90.71M
Diluted Earnings per Share	$1.64	$0.07	$2.30	($2.01)	$1.24	($7.59)	$2.10	$2.98	($0.24)	$2.78	($12.16)
Weighted Average Diluted Shares Outstanding	68.39M	85.97M	87.06M	87.42M	87.82M	88.60M	90.79M	91.56M	90.95M	92.06M	90.71M
Weighted Average Basic & Diluted Shares Outstanding	68.20M	87.80M	86.90M	87.40M	88.49M	89.04M	89.90M	91.31M	92.29M	92.91M	92.21M

This table shows Acadia Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	58	76	78	68	33	8.37	30	36	-1,178	4.11	11
Consolidated Net Income / (Loss)	60	79	81	71	34	9.06	38	38	-1,177	4.46	12
Net Income / (Loss) Continuing Operations	60	79	81	71	34	9.06	38	38	-1,177	4.46	12
Total Pre-Tax Income	80	99	106	99	38	13	50	40	-1,169	11	22
Total Operating Income	98	126	136	128	68	44	85	77	-1,130	49	60
Total Gross Profit	342	351	337	387	349	325	417	389	361	362	392
Total Revenue	743	768	796	816	774	771	869	852	821	829	866
Operating Revenue	743	768	796	816	774	771	869	852	821	829	866
Total Cost of Revenue	400	418	460	428	426	445	452	462	461	467	474
Operating Cost of Revenue	400	418	460	428	426	445	452	462	461	467	474
Total Operating Expenses	244	224	201	259	281	281	332	313	1,491	312	332
Selling, General & Admin Expense	170	173	158	190	194	188	213	211	255	214	242
Depreciation Expense	35	36	36	38	40	47	49	47	46	52	50
Other Operating Expenses / (Income)	12	12	0.00	12	12	12	13	12	12	12	12
Impairment Charge	-	-	1.00	10	-	-	1.45	0.00	-	-	7.36
Restructuring Charge	35	2.85	6.09	8.25	30	31	64	43	25	22	23
Other Special Charges / (Income)	-	0.00	0.00	0.00	-	3.50	-8.72	0.00	146	13	-2.36
Total Other Income / (Expense), net	-18	-27	-29	-30	-30	-30	-35	-37	-39	-38	-38
Interest Expense	-	-	29	30	30	30	35	37	39	38	38
Income Tax Expense	20	20	26	27	4.48	4.40	12	1.67	7.84	6.50	9.75
Net Income / (Loss) Attributable to Noncontrolling Interest	2.03	2.39	2.34	3.24	0.91	0.69	7.81	2.07	0.28	0.36	1.33
Basic Earnings per Share	$0.63	$0.84	$0.86	$0.74	$0.35	$0.09	$0.33	$0.40	($12.98)	$0.05	$0.12
Weighted Average Basic Shares Outstanding	90.95M	91.36M	91.63M	91.72M	91.62M	91.65M	90.33M	90.41M	90.71M	90.53M	90.82M
Diluted Earnings per Share	$0.64	$0.83	$0.85	$0.74	$0.36	$0.09	$0.33	$0.40	($12.98)	$0.05	$0.12
Weighted Average Diluted Shares Outstanding	90.95M	92.01M	92.04M	92.19M	92.06M	92.04M	90.44M	90.58M	90.71M	90.86M	91.37M
Weighted Average Basic & Diluted Shares Outstanding	92.29M	92.77M	92.87M	92.89M	92.91M	92.12M	92.35M	92.26M	92.21M	-	93.10M

This table details how cash moves in and out of Acadia Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-83	46	2.98	-14	49	325	-245	-36	2.42	-24	57
Net Cash From Operating Activities	240	361	400	414	333	659	374	381	462	130	132
Net Cash From Continuing Operating Activities	242	372	401	226	183	503	374	0.00	462	130	132
Net Income / (Loss) Continuing Operations	111	4.18	200	57	53	143	208	280	-16	264	-1,092
Consolidated Net Income / (Loss)	111	4.18	200	-175	110	-669	196	280	-16	264	-1,092
Depreciation Expense	64	135	143	80	88	95	107	118	132	150	189
Amortization Expense	6.71	10	9.86	10	12	13	4.07	3.26	3.32	4.09	4.86
Non-Cash Adjustments To Reconcile Net Income	35	216	36	58	48	122	49	-6.76	421	117	1,037
Changes in Operating Assets and Liabilities, net	26	6.53	13	19	-18	130	6.40	-14	-78	-406	-7.57
Net Cash From Investing Activities	-884	-660	-337	-361	-201	-282	1,013	-306	-397	-736	-556
Net Cash From Continuing Investing Activities	-884	-660	-337	-276	-148	-238	0.00	0.00	-397	-736	-556
Purchase of Property, Plant & Equipment	-303	-348	-274	-253	-233	-225	-245	-296	-424	-690	-572
Acquisitions	-575	-683	-18	0.00	-45	0.00	-139	-9.51	-0.35	-54	-8.17
Sale of Property, Plant & Equipment	-	-	5.25	0.00	12	0.09	3.49	7.07	29	10	24
Other Investing Activities, net	-5.10	-2.47	-49	-23	13	-13	-33	-7.25	-2.16	-2.98	-0.09
Net Cash From Financing Activities	564	359	-60	-67	-62	-51	-1,637	-111	-63	583	481
Net Cash From Continuing Financing Activities	564	359	-60	-64	-59	-48	0.00	0.00	-63	584	481
Repayment of Debt	-1,378	-1,976	-57	-62	-134	-1,073	-2,581	-114	-56	-73	-1,737
Repurchase of Common Equity	-	-8.85	-3.46	-3.41	-1.65	0.18	16	-12	0.00	0.00	-50
Payment of Dividends	-	-	0.00	0.00	-0.15	-0.92	-1.59	-1.00	-5.11	-2.97	-3.88
Issuance of Debt	1,618	1,659	0.69	0.83	77	1,025	925	0.00	40	655	2,269
Issuance of Common Equity	331	685	-	-	-	0.00	4.54	15	-41	5.18	4.41
Other Financing Activities, net	-7.45	-	-	-	-	-	-	-	0.00	0.00	-1.50
Cash Interest Paid	87	161	159	175	173	138	94	66	81	113	125
Cash Income Taxes Paid	-	-	-	-	32	-	79	86	66	28	30

This table details how cash moves in and out of Acadia Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	0.48	-23	-0.14	4.98	-5.84	15	40	-13	15	25	13
Net Cash From Operating Activities	116	-321	171	163	117	11	134	73	-86	62	162
Net Cash From Continuing Operating Activities	-346	-321	171	163	-13	11	134	73	-86	62	162
Net Income / (Loss) Continuing Operations	60	79	81	71	34	9.06	38	38	-1,177	4.46	12
Consolidated Net Income / (Loss)	60	79	81	71	34	9.06	38	38	-1,177	4.46	12
Depreciation Expense	35	36	36	38	40	47	49	47	46	52	50
Amortization Expense	0.84	1.02	1.02	1.03	1.03	1.06	1.22	1.24	1.35	1.25	1.26
Non-Cash Adjustments To Reconcile Net Income	-2.29	22	-7.46	20	83	14	4.34	6.81	1,013	7.14	16
Changes in Operating Assets and Liabilities, net	23	-459	61	33	-40	-59	41	-21	31	-3.75	82
Net Cash From Investing Activities	-110	-185	-155	-193	-203	-183	-151	-130	-92	-60	-33
Net Cash From Continuing Investing Activities	287	-185	-155	-193	533	-183	-151	-130	-92	-60	-33
Purchase of Property, Plant & Equipment	-139	-142	-154	-190	-203	-175	-168	-136	-93	-77	-39
Sale of Property, Plant & Equipment	29	9.06	1.15	0.02	0.21	0.04	17	6.53	0.70	16	10
Other Investing Activities, net	-0.23	-0.91	-2.03	-0.00	-0.04	-0.06	-0.05	-0.04	0.06	-0.03	-4.24
Net Cash From Financing Activities	-5.65	483	-16	35	81	187	57	44	193	24	-117
Net Cash From Continuing Financing Activities	57	484	-17	35	-502	187	57	44	193	24	-117
Repayment of Debt	-5.31	-27	-15	-15	-15	-1,724	-4.11	-4.06	-4.09	-59	-113
Repurchase of Common Equity	0.86	0.00	-	0.84	0.82	-49	-4.93	-0.24	3.95	-2.74	-1.06
Payment of Dividends	-1.63	-1.02	-0.48	-1.47	-	0.00	-1.99	-1.89	-	0.00	-2.59
Issuance of Common Equity	0.42	2.28	0.69	0.53	1.68	0.00	-	5.00	-0.59	0.74	0.25

This table presents Acadia Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	4,279	6,025	6,425	6,173	6,879	6,499	4,768	4,988	5,359	5,957	5,527
Total Current Assets	295	428	472	450	542	2,523	495	506	596	577	814
Cash & Equivalents	11	57	67	51	100	379	134	98	100	76	133
Accounts Receivable	217	263	297	318	289	274	281	322	361	365	441
Other Current Assets	67	108	107	82	65	61	80	86	134	136	240
Plant, Property, & Equipment, net	1,709	2,704	3,048	3,108	1,500	1,623	1,771	1,952	2,267	2,853	3,111
Total Noncurrent Assets	2,275	2,893	2,905	2,614	4,837	2,353	2,502	2,530	2,496	2,526	1,602
Goodwill	2,128	2,681	2,751	2,396	2,085	2,105	2,200	2,223	2,226	2,265	1,296
Intangible Assets	60	83	87	89	69	69	70	76	73	70	97
Noncurrent Deferred & Refundable Income Taxes	49	3.78	3.73	3.47	3.34	3.21	3.08	2.95	6.66	21	2.53
Other Noncurrent Operating Assets	39	125	63	125	153	176	229	228	190	170	207
Total Liabilities & Shareholders' Equity	4,279	6,025	6,425	6,173	6,879	6,499	4,768	4,988	5,359	5,957	5,527
Total Liabilities	2,588	3,839	3,829	3,810	4,341	4,545	2,185	2,087	2,471	2,766	3,387
Total Current Liabilities	290	343	377	416	464	1,308	405	388	886	578	525
Short-Term Debt	45	35	35	34	44	153	19	21	29	77	28
Accounts Payable	91	80	102	118	90	88	99	105	156	233	150
Accrued Expenses	73	123	141	151	69	178	126	111	532	88	137
Current Employee Benefit Liabilities	81	105	99	113	94	125	138	125	142	155	189
Other Current Liabilities	-	-	-	0.00	18	104	23	26	26	25	21
Total Noncurrent Liabilities	2,298	3,496	3,452	3,394	3,877	3,236	1,780	1,699	1,585	2,188	2,862
Long-Term Debt	2,195	3,253	3,205	3,159	3,105	2,969	1,479	1,365	1,343	1,880	2,472
Noncurrent Deferred & Payable Income Tax Liabilities	24	79	80	80	23	50	74	93	1.93	84	67
Other Noncurrent Operating Liabilities	79	165	166	154	262	217	111	241	241	224	324
Redeemable Noncontrolling Interest	8.06	18	22	29	33	55	65	88	106	117	192
Total Equity & Noncontrolling Interests	1,683	2,168	2,573	2,333	2,505	1,899	2,517	2,813	2,782	3,074	1,949
Total Preferred & Common Equity	1,683	2,168	2,573	2,333	2,505	1,899	2,517	2,813	2,782	3,074	1,949
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,683	2,168	2,573	2,333	2,505	1,899	2,517	2,813	2,782	3,074	1,949
Common Stock	1,574	2,497	2,518	2,543	2,559	2,581	2,637	2,659	2,650	2,686	2,715
Retained Earnings	214	220	429	253	362	-310	-120	153	132	387	-766

This table presents Acadia Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	5,044	5,150	5,346	5,517	5,678	5,870	6,148	6,308	6,413	5,546	5,546
Total Current Assets	538	579	703	611	645	652	639	692	748	837	845
Cash & Equivalents	64	112	100	77	77	82	91	131	119	158	171
Accounts Receivable	346	346	363	386	389	384	397	409	431	472	471
Other Current Assets	128	121	241	147	179	186	151	152	198	207	203
Plant, Property, & Equipment, net	1,998	2,074	2,146	2,376	2,498	2,680	2,956	3,064	3,092	3,107	3,090
Total Noncurrent Assets	2,508	2,497	2,497	2,530	2,535	2,539	2,553	2,553	2,573	1,603	1,611
Goodwill	2,223	2,223	2,226	2,261	2,261	2,265	2,276	2,276	2,286	1,301	1,303
Intangible Assets	76	72	74	73	73	73	79	79	85	99	100
Noncurrent Deferred & Refundable Income Taxes	2.92	2.89	2.85	2.78	2.74	2.71	23	25	28	2.49	2.46
Other Noncurrent Operating Assets	206	200	195	193	197	198	174	172	174	200	205
Total Liabilities & Shareholders' Equity	5,044	5,150	5,346	5,517	5,678	5,870	6,148	6,308	6,413	5,546	5,546
Total Liabilities	2,114	2,139	2,536	2,542	2,613	2,724	2,974	3,085	3,123	3,378	3,354
Total Current Liabilities	378	432	865	482	547	610	473	524	518	489	538
Short-Term Debt	21	24	27	61	67	72	16	20	24	33	33
Accounts Payable	126	149	150	156	160	201	204	220	180	142	135
Accrued Expenses	110	122	540	120	159	168	88	105	126	137	172
Current Employee Benefit Liabilities	95	111	122	118	135	141	140	156	166	157	178
Other Current Liabilities	26	26	26	27	27	27	25	23	21	21	21
Total Noncurrent Liabilities	1,736	1,706	1,671	2,060	2,067	2,115	2,500	2,561	2,605	2,889	2,817
Long-Term Debt	1,400	1,372	1,350	1,794	1,775	1,805	2,184	2,247	2,285	2,494	2,382
Noncurrent Deferred & Payable Income Tax Liabilities	93	93	70	16	37	54	81	80	94	77	87
Other Noncurrent Operating Liabilities	244	241	251	250	255	256	235	234	226	318	348
Redeemable Noncontrolling Interest	90	91	98	109	112	115	132	146	170	210	213
Total Equity & Noncontrolling Interests	2,840	2,921	2,713	2,866	2,953	3,032	3,042	3,078	3,120	1,958	1,979
Total Preferred & Common Equity	2,840	2,921	2,713	2,866	2,953	3,032	3,042	3,078	3,120	1,958	1,979
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,840	2,921	2,713	2,866	2,953	3,032	3,042	3,078	3,120	1,958	1,979
Common Stock	2,620	2,629	2,639	2,658	2,666	2,677	2,693	2,703	2,709	2,720	2,730
Retained Earnings	219	292	74	208	287	355	348	375	412	-762	-751

This table displays calculated financial ratios and metrics derived from Acadia Healthcare's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	92,258,166.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	92,258,166.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-11.95
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	77.50%	55.92%	0.86%	-33.80%	5.44%	4.06%	10.74%	12.79%	12.20%	7.69%	5.04%
EBITDA Growth	62.55%	5.25%	57.26%	-39.41%	6.68%	14.04%	12.79%	15.56%	-65.77%	228.96%	-219.57%
EBIT Growth	55.70%	-21.07%	92.65%	-38.97%	5.47%	16.32%	16.31%	17.51%	-88.08%	810.20%	-302.03%
NOPAT Growth	59.52%	-85.20%	1,181.39%	-38.24%	-15.92%	33.26%	12.72%	16.49%	-88.85%	905.92%	-282.81%
Net Income Growth	34.24%	-96.25%	4,679.43%	-187.92%	162.75%	-707.69%	129.22%	43.19%	-105.59%	1,788.81%	-512.85%
EPS Growth	9.33%	-95.73%	3,185.71%	-187.39%	161.69%	-712.10%	127.67%	41.90%	-108.05%	1,258.33%	-537.41%
Operating Cash Flow Growth	108.53%	50.36%	10.54%	3.63%	-19.60%	97.90%	-43.16%	1.63%	21.49%	-71.95%	1.70%
Free Cash Flow Firm Growth	-184.17%	21.50%	99.75%	12,931.96%	334.99%	-85.57%	-181.01%	178.27%	-65.82%	-957.62%	84.95%
Invested Capital Growth	110.04%	38.15%	6.49%	-4.56%	-34.46%	-1.64%	14.50%	3.10%	-0.71%	21.93%	-11.12%
Revenue Q/Q Growth	12.54%	7.90%	0.69%	-36.56%	2.31%	69.94%	2.31%	3.24%	2.36%	1.01%	1.45%
EBITDA Q/Q Growth	13.31%	6.95%	3.88%	-41.25%	12.04%	45.26%	18.34%	-2.59%	0.80%	-4.08%	-259.05%
EBIT Q/Q Growth	13.25%	3.44%	4.41%	-39.43%	14.80%	29.68%	24.88%	-3.70%	-6.97%	-6.22%	-439.78%
NOPAT Q/Q Growth	12.88%	269.60%	12.28%	-46.67%	47.17%	145.42%	22.80%	-4.48%	-6.97%	-4.21%	-383.11%
Net Income Q/Q Growth	11.86%	226.62%	16.50%	-177.74%	152.17%	-749.52%	129.70%	-2.90%	-27.61%	-9.02%	-1,018.77%
EPS Q/Q Growth	7.89%	-30.00%	17.35%	-177.61%	151.24%	-771.68%	127.93%	-3.87%	-4.35%	-9.15%	-1,130.51%
Operating Cash Flow Q/Q Growth	27.65%	0.98%	7.08%	-0.08%	-2.50%	11.36%	-19.15%	4.30%	0.60%	0.31%	-60.61%
Free Cash Flow Firm Q/Q Growth	-8.34%	31.61%	-100.74%	110.23%	348.85%	55.72%	-112.58%	197.04%	-68.65%	-15.38%	73.03%
Invested Capital Q/Q Growth	4.19%	-8.11%	1.20%	-6.30%	-34.82%	-34.77%	8.94%	-1.58%	1.77%	2.65%	-17.76%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	44.86%	44.48%	45.19%	40.63%	44.86%	44.76%	46.26%	46.62%	46.31%	46.38%	45.04%
EBITDA Margin	18.68%	12.61%	19.66%	17.99%	18.21%	19.95%	20.32%	20.82%	6.35%	19.40%	-22.09%
Operating Margin	14.84%	7.51%	14.35%	13.23%	13.23%	14.79%	15.53%	16.18%	1.72%	14.53%	-27.95%
EBIT Margin	14.84%	7.51%	14.35%	13.23%	13.23%	14.79%	15.53%	16.18%	1.72%	14.53%	-27.95%
Profit (Net Income) Margin	6.09%	0.15%	6.94%	-9.21%	5.48%	-32.02%	8.45%	10.73%	-0.53%	8.39%	-32.96%
Tax Burden Percent	67.66%	12.67%	84.29%	-260.38%	140.47%	-364.10%	70.92%	74.85%	61.75%	77.36%	102.44%
Interest Burden Percent	60.68%	15.38%	57.36%	26.75%	29.50%	59.47%	76.71%	88.56%	-50.37%	74.61%	115.14%
Effective Tax Rate	32.40%	87.33%	15.71%	14.70%	32.00%	22.09%	24.50%	25.15%	0.00%	22.64%	0.00%
Return on Invested Capital (ROIC)	6.34%	0.58%	6.22%	3.81%	3.97%	6.73%	7.13%	7.66%	0.84%	7.68%	-13.53%
ROIC Less NNEP Spread (ROIC-NNEP)	1.86%	-0.26%	1.59%	-8.55%	0.61%	-61.61%	2.20%	5.05%	-3.13%	1.97%	-34.43%
Return on Net Nonoperating Assets (RNNOA)	2.33%	-0.37%	2.13%	-10.89%	0.53%	-36.52%	1.49%	2.55%	-1.39%	1.02%	-27.43%
Return on Equity (ROE)	8.67%	0.22%	8.35%	-7.08%	4.49%	-29.79%	8.62%	10.21%	-0.54%	8.70%	-40.96%
Cash Return on Invested Capital (CROIC)	-64.64%	-31.46%	-0.07%	8.48%	45.60%	8.38%	-6.38%	4.61%	1.56%	-12.08%	-1.75%
Operating Return on Assets (OROA)	8.37%	4.16%	6.63%	4.00%	4.07%	4.62%	6.38%	8.66%	0.97%	8.10%	-16.12%
Return on Assets (ROA)	3.44%	0.08%	3.21%	-2.79%	1.69%	-10.00%	3.47%	5.74%	-0.30%	4.67%	-19.02%
Return on Common Equity (ROCE)	8.64%	0.21%	8.28%	-7.01%	4.44%	-29.20%	8.39%	9.93%	-0.52%	8.38%	-38.59%
Return on Equity Simple (ROE_SIMPLE)	6.62%	0.19%	7.76%	-7.52%	4.40%	-35.23%	7.77%	9.96%	-0.56%	8.60%	0.00%
Net Operating Profit after Tax (NOPAT)	184	27	348	215	181	241	271	316	35	355	-648
NOPAT Margin	10.03%	0.95%	12.09%	11.28%	9.00%	11.52%	11.73%	12.11%	1.20%	11.24%	-19.56%
Net Nonoperating Expense Percent (NNEP)	4.48%	0.84%	4.63%	12.36%	3.35%	68.34%	4.94%	2.61%	3.98%	5.71%	20.90%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	7.53%	0.85%	7.05%	-14.57%
Cost of Revenue to Revenue	55.14%	55.52%	54.81%	59.37%	55.14%	55.24%	53.74%	53.38%	53.69%	53.62%	54.96%
SG&A Expenses to Revenue	17.67%	21.57%	22.33%	18.57%	23.08%	22.49%	22.85%	23.27%	22.91%	23.56%	26.17%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	30.02%	36.97%	30.84%	27.41%	31.63%	29.97%	30.72%	30.44%	44.59%	31.85%	72.99%
Earnings before Interest and Taxes (EBIT)	271	214	413	252	266	309	360	422	50	458	-926
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	342	360	566	343	366	417	470	543	186	612	-732
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.66	1.34	1.11	0.97	1.17	2.35	2.17	2.66	2.58	1.20	0.67
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	8.37	0.00	22.07	14.57	14.85	4.98	2.35
Price to Revenue (P/Rev)	2.45	1.02	1.00	1.19	1.47	2.14	2.36	2.87	2.45	1.17	0.40
Price to Earnings (P/E)	39.78	471.48	14.35	0.00	27.01	0.00	28.64	27.42	0.00	14.41	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.51%	0.21%	6.97%	0.00%	3.70%	0.00%	3.49%	3.65%	0.00%	6.94%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.71	1.13	1.05	0.99	1.67	2.05	1.72	2.12	2.06	1.12	0.86
Enterprise Value to Revenue (EV/Rev)	3.67	2.15	2.11	2.86	3.00	3.48	3.03	3.40	2.92	1.80	1.17
Enterprise Value to EBITDA (EV/EBITDA)	19.65	17.08	10.72	15.88	16.48	17.44	14.89	16.31	45.95	9.28	0.00
Enterprise Value to EBIT (EV/EBIT)	24.73	28.68	14.68	21.60	22.67	23.53	19.48	20.99	169.79	12.40	0.00
Enterprise Value to NOPAT (EV/NOPAT)	36.59	226.30	17.42	25.32	33.34	30.20	25.81	28.04	242.55	16.02	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	27.93	17.00	15.17	13.14	18.10	11.04	18.71	23.30	18.49	43.80	29.32
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	11.39	2.90	24.24	0.00	46.61	131.48	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.33	1.50	1.25	1.35	1.24	1.60	0.62	0.48	0.48	0.61	1.17
Long-Term Debt to Equity	1.30	1.49	1.24	1.34	1.22	1.52	0.62	0.47	0.46	0.59	1.15
Financial Leverage	1.25	1.41	1.34	1.27	0.86	0.59	0.68	0.50	0.44	0.52	0.80
Leverage Ratio	2.52	2.66	2.60	2.54	2.66	2.98	2.48	1.78	1.79	1.86	2.15
Compound Leverage Factor	1.53	0.41	1.49	0.68	0.79	1.77	1.90	1.58	-0.90	1.39	2.48
Debt to Total Capital	56.99%	60.07%	55.52%	57.48%	55.37%	61.50%	38.46%	32.33%	32.21%	38.01%	53.87%
Short-Term Debt to Total Capital	1.15%	0.64%	0.60%	0.61%	0.77%	3.02%	0.44%	0.50%	0.69%	1.49%	0.61%
Long-Term Debt to Total Capital	55.84%	59.43%	54.93%	56.87%	54.60%	58.48%	38.02%	31.83%	31.52%	36.52%	53.26%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.20%	0.32%	0.38%	0.52%	0.58%	1.09%	1.56%	2.06%	2.48%	2.28%	4.13%
Common Equity to Total Capital	42.81%	39.61%	44.09%	42.00%	44.05%	37.41%	59.98%	65.61%	65.31%	59.71%	42.00%
Debt to EBITDA	6.56	9.14	5.73	9.32	8.61	7.49	3.43	2.55	7.37	3.20	-3.42
Net Debt to EBITDA	6.52	8.98	5.61	9.17	8.34	6.58	3.15	2.37	6.84	3.07	-3.23
Long-Term Debt to EBITDA	6.42	9.04	5.67	9.22	8.49	7.12	3.39	2.51	7.22	3.07	-3.38
Debt to NOPAT	12.21	121.08	9.31	14.86	17.43	12.97	5.95	4.38	38.92	5.52	-3.86
Net Debt to NOPAT	12.15	118.98	9.12	14.63	16.88	11.39	5.45	4.07	36.08	5.30	-3.65
Long-Term Debt to NOPAT	11.96	119.80	9.21	14.70	17.19	12.33	5.88	4.32	38.09	5.30	-3.81
Altman Z-Score	1.75	1.11	1.22	0.86	0.91	1.23	2.22	3.03	2.29	1.67	0.15
Noncontrolling Interest Sharing Ratio	0.31%	0.67%	0.84%	1.03%	1.26%	1.97%	2.66%	2.80%	3.35%	3.67%	5.79%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.02	1.25	1.25	1.08	1.17	1.93	1.22	1.30	0.67	1.00	1.55
Quick Ratio	0.79	0.93	0.97	0.89	0.84	0.50	1.03	1.08	0.52	0.76	1.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,871	-1,468	-3.72	478	2,078	300	-243	190	65	-558	-84
Operating Cash Flow to CapEx	79.43%	103.80%	148.58%	163.55%	150.69%	292.97%	155.18%	131.65%	117.13%	19.07%	24.07%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	2.59	11.09	1.90	-2.39	2.73	0.79	-4.79	-0.60
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	2.24	1.78	4.17	3.68	5.46	5.63	1.11	0.94
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.87	0.60	2.74	1.31	1.31	0.82	-4.73	-2.97
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.56	0.55	0.46	0.30	0.31	0.31	0.41	0.54	0.57	0.56	0.58
Accounts Receivable Turnover	10.92	11.89	10.27	6.19	6.62	7.43	8.34	8.65	8.56	8.68	8.22
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.32	1.29	1.00	0.62	0.87	1.34	1.36	1.40	1.39	1.23	1.11
Accounts Payable Turnover	14.41	18.48	17.30	10.28	10.65	12.97	13.35	13.71	12.06	8.70	9.50
Days Sales Outstanding (DSO)	33.42	30.70	35.54	58.93	55.15	49.11	43.75	42.21	42.62	42.05	44.40
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	25.33	19.75	21.10	35.51	34.28	28.15	27.35	26.63	30.28	41.96	38.40
Cash Conversion Cycle (CCC)	8.08	10.96	14.44	23.42	20.87	20.96	16.41	15.59	12.34	0.09	6.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,921	5,416	5,768	5,505	3,608	3,549	4,063	4,189	4,159	5,071	4,507
Invested Capital Turnover	0.63	0.61	0.51	0.34	0.44	0.58	0.61	0.63	0.70	0.68	0.69
Increase / (Decrease) in Invested Capital	2,054	1,496	352	-263	-1,897	-59	514	126	-30	912	-564
Enterprise Value (EV)	6,715	6,145	6,062	5,441	6,025	7,272	7,005	8,866	8,548	5,681	3,867
Market Capitalization	4,478	2,896	2,867	2,269	2,942	4,473	5,459	7,489	7,171	3,683	1,309
Book Value per Share	$23.48	$24.77	$29.29	$26.44	$28.29	$21.34	$27.99	$30.92	$30.17	$33.09	$21.13
Tangible Book Value per Share	($7.04)	($6.82)	($3.02)	($1.72)	$3.97	($3.08)	$2.75	$5.65	$5.23	$7.95	$6.03
Total Capital	3,932	5,473	5,835	5,556	5,688	5,077	4,197	4,287	4,259	5,148	4,641
Total Debt	2,241	3,288	3,240	3,193	3,149	3,122	1,614	1,386	1,372	1,957	2,500
Total Long-Term Debt	2,195	3,253	3,205	3,159	3,105	2,969	1,595	1,365	1,343	1,880	2,472
Net Debt	2,230	3,231	3,173	3,143	3,050	2,744	1,480	1,288	1,272	1,881	2,367
Capital Expenditures (CapEx)	303	348	269	253	221	225	241	289	395	680	548
Debt-free, Cash-free Net Working Capital (DFCFNWC)	39	63	62	18	23	990	-25	41	-361	0.08	184
Debt-free Net Working Capital (DFNWC)	50	120	129	68	122	1,369	109	139	-261	76	317
Net Working Capital (NWC)	4.53	85	94	34	79	1,215	90	118	-290	-0.43	289
Net Nonoperating Expense (NNE)	72	23	148	390	71	910	76	36	51	90	444
Net Nonoperating Obligations (NNO)	2,230	3,231	3,173	3,143	1,069	1,594	1,480	1,288	1,272	1,881	2,367
Total Depreciation and Amortization (D&A)	70	145	153	91	100	108	111	121	136	154	194
Debt-free, Cash-free Net Working Capital to Revenue	2.11%	2.20%	2.14%	0.93%	1.13%	47.37%	-1.08%	1.59%	-12.31%	0.00%	5.56%
Debt-free Net Working Capital to Revenue	2.73%	4.20%	4.48%	3.58%	6.09%	65.49%	4.70%	5.33%	-8.90%	2.42%	9.58%
Net Working Capital to Revenue	0.25%	2.98%	3.27%	1.79%	3.92%	58.15%	3.90%	4.51%	-9.89%	-0.01%	8.72%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.65	$0.07	$2.30	($2.01)	$1.24	($7.65)	$2.15	$3.05	($0.24)	$2.79	($12.16)
Adjusted Weighted Average Basic Shares Outstanding	68.09M	85.70M	86.95M	87.29M	87.61M	87.88M	88.77M	89.68M	90.95M	91.62M	90.71M
Adjusted Diluted Earnings per Share	$1.64	$0.07	$2.30	($2.01)	$1.24	($7.59)	$2.10	$2.98	($0.24)	$2.78	($12.16)
Adjusted Weighted Average Diluted Shares Outstanding	68.39M	85.97M	87.06M	87.29M	87.82M	88.60M	90.79M	91.56M	90.95M	92.06M	90.71M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($2.01)	$1.24	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	87.22M	87.55M	87.95M	88.46M	88.49M	89.04M	89.90M	91.31M	92.29M	92.91M	92.21M
Normalized Net Operating Profit after Tax (NOPAT)	216	187	369	259	214	259	299	334	355	404	272
Normalized NOPAT Margin	11.78%	6.55%	12.83%	13.60%	10.63%	12.41%	12.94%	12.79%	12.11%	12.81%	8.20%
Pre Tax Income Margin	9.00%	1.16%	8.23%	3.54%	3.90%	8.79%	11.92%	14.33%	-0.87%	10.84%	-32.18%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	1.37	1.42	1.95	3.54	6.06	0.61	3.94	-6.61
NOPAT to Interest Expense	0.00	0.00	0.00	1.16	0.96	1.52	2.67	4.53	0.43	3.05	-4.62
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	-0.01	0.24	0.53	1.16	1.91	-4.19	-1.91	-10.52
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	-0.21	-0.21	0.10	0.30	0.39	-4.38	-2.80	-8.53
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.14%	-0.14%	0.81%	0.36%	-32.61%	1.12%	-0.36%
Augmented Payout Ratio	0.00%	211.83%	1.73%	-1.94%	1.64%	-0.11%	-7.52%	4.54%	-315.70%	1.12%	-4.94%

This table displays calculated financial ratios and metrics derived from Acadia Healthcare's official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	92,258,166.00	92,211,777.00	92,211,777.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	92,258,166.00	92,211,777.00	92,211,777.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-12.76	0.04	0.12
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.00%	9.06%	8.85%	8.70%	4.23%	0.32%	9.19%	4.41%	6.10%	7.57%	-0.39%
EBITDA Growth	1.11%	18.39%	15.00%	170.57%	-19.33%	-44.48%	-21.62%	-25.04%	-1,096.90%	11.92%	-17.35%
EBIT Growth	-3.69%	19.33%	15.58%	147.40%	-30.86%	-66.17%	-37.22%	-40.38%	-1,760.13%	12.24%	-29.31%
NOPAT Growth	0.39%	22.36%	15.03%	149.03%	-18.38%	-71.43%	-37.26%	-21.10%	-1,417.33%	-32.10%	-48.09%
Net Income Growth	-5.37%	18.35%	9.88%	133.11%	-43.89%	-88.49%	-53.06%	-46.31%	-3,611.11%	-50.75%	-67.68%
EPS Growth	-1.54%	15.28%	7.59%	130.96%	-43.75%	-89.16%	-61.18%	-45.95%	-3,705.56%	-44.44%	-63.64%
Operating Cash Flow Growth	2.43%	-823.48%	4.51%	18.33%	0.34%	103.57%	-22.00%	-55.12%	-173.94%	436.12%	21.39%
Free Cash Flow Firm Growth	296.10%	-69.79%	-500.93%	-3,648.20%	-924.39%	-36.79%	-8.46%	38.64%	73.36%	253.38%	305.42%
Invested Capital Growth	-0.71%	10.88%	12.40%	20.88%	21.93%	11.14%	10.99%	10.93%	-11.12%	-14.13%	-17.25%
Revenue Q/Q Growth	-1.00%	3.40%	3.64%	2.46%	-5.08%	-0.48%	12.81%	-2.03%	-3.54%	0.89%	4.47%
EBITDA Q/Q Growth	156.86%	21.34%	5.68%	-3.21%	-35.00%	-16.48%	49.17%	-7.43%	-964.36%	109.51%	8.65%
EBIT Q/Q Growth	136.32%	28.03%	7.58%	-5.26%	-47.02%	-37.35%	99.63%	-10.03%	-1,575.38%	104.36%	22.09%
NOPAT Q/Q Growth	138.77%	36.53%	2.48%	-9.63%	-35.45%	-52.21%	125.04%	13.65%	-1,177.73%	102.54%	67.06%
Net Income Q/Q Growth	127.73%	31.82%	2.60%	-11.69%	-53.02%	-72.97%	318.53%	1.00%	-3,172.37%	100.38%	174.64%
EPS Q/Q Growth	126.78%	29.69%	2.41%	-12.94%	-51.35%	-75.00%	266.67%	21.21%	-3,345.00%	100.39%	140.00%
Operating Cash Flow Q/Q Growth	-15.63%	-376.25%	153.27%	-4.69%	-28.46%	-90.17%	1,063.23%	-45.16%	-217.87%	171.30%	163.39%
Free Cash Flow Firm Q/Q Growth	609.51%	-454.21%	-17.43%	-76.85%	-12.06%	41.22%	6.89%	-0.06%	51.35%	437.81%	24.92%
Invested Capital Q/Q Growth	1.77%	14.29%	1.57%	2.32%	2.65%	4.18%	1.44%	2.26%	-17.76%	0.65%	-2.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	46.10%	45.64%	47.27%	47.51%	45.03%	42.21%	47.95%	45.73%	43.90%	43.65%	45.24%
EBITDA Margin	18.13%	21.28%	21.70%	20.49%	14.03%	11.78%	15.57%	14.71%	-131.85%	12.42%	12.92%
Operating Margin	13.26%	16.41%	17.04%	15.75%	8.79%	5.54%	9.80%	9.00%	-137.58%	5.95%	6.95%
EBIT Margin	13.26%	16.41%	17.04%	15.75%	8.79%	5.54%	9.80%	9.00%	-137.58%	5.95%	6.95%
Profit (Net Income) Margin	8.04%	10.26%	10.15%	8.75%	4.33%	1.18%	4.36%	4.50%	-143.31%	0.54%	1.42%
Tax Burden Percent	74.73%	79.69%	75.91%	72.41%	88.22%	67.30%	75.87%	95.83%	100.67%	40.72%	55.71%
Interest Burden Percent	81.21%	78.41%	78.50%	76.71%	55.83%	31.58%	58.73%	52.20%	103.47%	22.24%	36.57%
Effective Tax Rate	25.27%	20.31%	24.09%	27.59%	11.78%	32.70%	24.13%	4.17%	0.00%	59.28%	44.29%
Return on Invested Capital (ROIC)	6.95%	8.66%	8.67%	7.89%	5.30%	2.34%	4.71%	5.40%	-66.62%	1.66%	2.66%
ROIC Less NNEP Spread (ROIC-NNEP)	5.87%	7.28%	7.21%	6.48%	3.62%	1.33%	3.34%	3.64%	-84.80%	0.97%	1.69%
Return on Net Nonoperating Assets (RNNOA)	2.60%	3.86%	3.62%	3.34%	1.88%	0.84%	2.07%	2.25%	-67.56%	0.81%	1.37%
Return on Equity (ROE)	9.55%	12.52%	12.29%	11.23%	7.18%	3.19%	6.79%	7.66%	-134.17%	2.47%	4.03%
Cash Return on Invested Capital (CROIC)	1.56%	-9.22%	-10.31%	-10.71%	-12.08%	-4.88%	-5.59%	-5.97%	-1.75%	2.09%	5.36%
Operating Return on Assets (OROA)	7.50%	9.30%	9.62%	8.77%	4.90%	3.00%	5.28%	4.78%	-79.38%	3.43%	3.95%
Return on Assets (ROA)	4.55%	5.81%	5.73%	4.87%	2.41%	0.64%	2.35%	2.39%	-82.68%	0.31%	0.80%
Return on Common Equity (ROCE)	9.23%	12.10%	11.88%	10.83%	6.91%	3.06%	6.51%	7.32%	-126.40%	2.31%	3.76%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-0.12%	0.13%	9.59%	0.00%	6.40%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	74	100	103	93	60	29	65	73	-791	20	34
NOPAT Margin	9.91%	13.08%	12.93%	11.41%	7.76%	3.73%	7.43%	8.62%	-96.31%	2.42%	3.87%
Net Nonoperating Expense Percent (NNEP)	1.08%	1.38%	1.45%	1.41%	1.68%	1.01%	1.37%	1.76%	18.18%	0.70%	0.97%
Return On Investment Capital (ROIC_SIMPLE)	1.77%	-	-	-	1.19%	0.55%	1.21%	1.35%	-17.78%	0.45%	0.76%
Cost of Revenue to Revenue	53.90%	54.36%	52.73%	52.49%	54.97%	57.79%	52.05%	54.27%	56.10%	56.35%	54.76%
SG&A Expenses to Revenue	22.93%	22.58%	23.32%	23.33%	25.05%	24.41%	24.49%	24.74%	31.07%	25.79%	27.92%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	32.84%	29.23%	30.23%	31.75%	36.24%	36.68%	38.16%	36.73%	181.48%	37.70%	38.29%
Earnings before Interest and Taxes (EBIT)	98	126	136	128	68	43	85	77	-1,130	49	60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	135	163	173	167	109	91	135	125	-1,083	103	112
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.58	2.55	2.12	1.94	1.20	0.93	0.68	0.73	0.67	1.10	1.38
Price to Tangible Book Value (P/TBV)	14.85	13.74	10.14	8.49	4.98	4.10	2.89	3.05	2.35	3.86	4.73
Price to Revenue (P/Rev)	2.45	2.44	2.05	1.89	1.17	0.89	0.65	0.70	0.40	0.64	0.81
Price to Earnings (P/E)	0.00	0.00	0.00	20.98	14.41	15.02	15.01	21.30	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	4.77%	6.94%	6.66%	6.66%	4.70%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.06	1.93	1.69	1.58	1.12	0.96	0.82	0.85	0.86	1.04	1.17
Enterprise Value to Revenue (EV/Rev)	2.92	3.07	2.66	2.50	1.80	1.60	1.35	1.42	1.17	1.40	1.54
Enterprise Value to EBITDA (EV/EBITDA)	45.95	43.49	34.81	12.22	9.28	9.38	8.71	10.10	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	169.79	129.92	91.44	15.96	12.40	13.50	13.48	17.05	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	242.55	185.60	130.63	21.07	16.02	17.77	17.75	20.30	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	18.49	95.12	78.27	60.31	43.80	10.94	10.29	13.87	29.32	26.02	24.60
Enterprise Value to Free Cash Flow (EV/FCFF)	131.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	46.24	19.73
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.48	0.62	0.60	0.60	0.61	0.69	0.70	0.70	1.17	1.17	1.10
Long-Term Debt to Equity	0.46	0.60	0.58	0.57	0.59	0.69	0.70	0.69	1.15	1.15	1.09
Financial Leverage	0.44	0.53	0.50	0.52	0.52	0.63	0.62	0.62	0.80	0.84	0.81
Leverage Ratio	1.79	1.79	1.78	1.88	1.86	1.90	1.91	1.91	2.15	2.19	2.19
Compound Leverage Factor	1.45	1.40	1.40	1.44	1.04	0.60	1.12	1.00	2.23	0.49	0.80
Debt to Total Capital	32.21%	38.41%	37.53%	37.36%	38.01%	40.94%	41.29%	41.24%	53.87%	53.82%	52.42%
Short-Term Debt to Total Capital	0.69%	1.27%	1.36%	1.43%	1.49%	0.30%	0.37%	0.44%	0.61%	0.69%	0.71%
Long-Term Debt to Total Capital	31.52%	37.14%	36.17%	35.93%	36.52%	40.64%	40.92%	40.81%	53.26%	53.13%	51.71%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	2.48%	2.26%	2.28%	2.28%	2.28%	2.46%	2.65%	3.03%	4.13%	4.47%	4.62%
Common Equity to Total Capital	65.31%	59.32%	60.19%	60.36%	59.71%	56.59%	56.06%	55.73%	42.00%	41.71%	42.96%
Debt to EBITDA	7.37	8.78	7.87	2.94	3.20	4.08	4.52	5.02	-3.42	-3.51	-3.24
Net Debt to EBITDA	6.84	8.41	7.54	2.81	3.07	3.91	4.26	4.76	-3.23	-3.29	-3.01
Long-Term Debt to EBITDA	7.22	8.49	7.59	2.83	3.07	4.05	4.48	4.97	-3.38	-3.46	-3.20
Debt to NOPAT	38.92	37.46	29.54	5.07	5.52	7.73	9.21	10.09	-3.86	-3.92	-3.65
Net Debt to NOPAT	36.08	35.90	28.30	4.85	5.30	7.41	8.67	9.57	-3.65	-3.68	-3.39
Long-Term Debt to NOPAT	38.09	36.22	28.47	4.88	5.30	7.67	9.12	9.98	-3.81	-3.87	-3.60
Altman Z-Score	2.32	2.42	2.15	1.99	1.46	1.22	1.08	1.12	0.03	0.90	1.01
Noncontrolling Interest Sharing Ratio	3.35%	3.38%	3.33%	3.56%	3.67%	3.93%	4.09%	4.42%	5.79%	6.41%	6.62%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.67	1.27	1.18	1.07	1.00	1.35	1.32	1.44	1.55	1.71	1.57
Quick Ratio	0.52	0.96	0.85	0.76	0.76	1.03	1.03	1.06	1.09	1.29	1.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	103	-366	-430	-760	-852	-501	-466	-467	-227	767	958
Operating Cash Flow to CapEx	105.79%	-240.93%	111.80%	85.76%	57.41%	6.57%	88.32%	56.44%	-93.30%	102.24%	569.88%
Free Cash Flow to Firm to Interest Expense	0.00	-13.45	-14.74	-25.41	-28.33	-17.16	-13.27	-12.74	-5.79	20.00	25.09
Operating Cash Flow to Interest Expense	0.00	-11.81	5.87	5.45	3.88	0.39	3.80	2.00	-2.20	1.61	4.25
Operating Cash Flow Less CapEx to Interest Expense	0.00	-16.71	0.62	-0.91	-2.88	-5.59	-0.50	-1.54	-4.56	0.04	3.50
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.57	0.57	0.56	0.56	0.56	0.54	0.54	0.53	0.58	0.58	0.57
Accounts Receivable Turnover	8.56	8.17	8.32	8.36	8.68	8.06	8.10	8.02	8.22	7.76	7.66
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.39	1.37	1.34	1.29	1.23	1.18	1.16	1.13	1.11	1.11	1.09
Accounts Payable Turnover	12.06	11.34	10.58	9.48	8.70	9.55	9.02	9.16	9.50	10.64	10.50
Days Sales Outstanding (DSO)	42.62	44.68	43.89	43.64	42.05	45.26	45.09	45.54	44.40	47.01	47.65
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	30.28	32.18	34.49	38.48	41.96	38.24	40.45	39.86	38.40	34.29	34.76
Cash Conversion Cycle (CCC)	12.34	12.50	9.40	5.15	0.09	7.02	4.64	5.67	6.00	12.72	12.89
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	4,159	4,754	4,829	4,940	5,071	5,283	5,359	5,480	4,507	4,537	4,435
Invested Capital Turnover	0.70	0.66	0.67	0.69	0.68	0.63	0.63	0.63	0.69	0.69	0.69
Increase / (Decrease) in Invested Capital	-30	467	533	853	912	529	531	540	-564	-747	-924
Enterprise Value (EV)	8,548	9,193	8,142	7,798	5,681	5,059	4,372	4,647	3,867	4,735	5,179
Market Capitalization	7,171	7,305	6,266	5,889	3,683	2,817	2,090	2,287	1,309	2,157	2,723
Book Value per Share	$30.17	$31.37	$31.83	$32.64	$33.09	$32.74	$33.41	$33.79	$21.13	$21.24	$21.79
Tangible Book Value per Share	$5.23	$5.82	$6.66	$7.47	$7.95	$7.39	$7.84	$8.11	$6.03	$6.05	$6.34
Total Capital	4,259	4,831	4,906	5,023	5,148	5,375	5,491	5,599	4,641	4,695	4,606
Total Debt	1,372	1,856	1,841	1,877	1,957	2,201	2,267	2,309	2,500	2,527	2,415
Total Long-Term Debt	1,343	1,794	1,775	1,805	1,880	2,184	2,247	2,285	2,472	2,494	2,382
Net Debt	1,272	1,778	1,764	1,794	1,881	2,109	2,136	2,190	2,367	2,368	2,243
Capital Expenditures (CapEx)	110	133	153	190	203	175	151	130	92	60	28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-361	113	88	32	0.08	91	57	136	184	222	169
Debt-free Net Working Capital (DFNWC)	-261	190	165	114	76	182	188	254	317	380	340
Net Working Capital (NWC)	-290	128	99	43	-0.43	166	168	230	289	348	308
Net Nonoperating Expense (NNE)	14	22	22	22	27	20	27	35	386	16	21
Net Nonoperating Obligations (NNO)	1,272	1,778	1,764	1,794	1,881	2,109	2,136	2,190	2,367	2,368	2,243
Total Depreciation and Amortization (D&A)	36	37	37	39	41	48	50	49	47	54	52
Debt-free, Cash-free Net Working Capital to Revenue	-12.31%	3.76%	2.88%	1.03%	0.00%	2.87%	1.76%	4.16%	5.56%	6.58%	5.02%
Debt-free Net Working Capital to Revenue	-8.90%	6.35%	5.41%	3.66%	2.42%	5.76%	5.83%	7.79%	9.58%	11.28%	10.10%
Net Working Capital to Revenue	-9.89%	4.29%	3.23%	1.36%	-0.01%	5.25%	5.20%	7.04%	8.72%	10.32%	9.14%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.63	$0.84	$0.86	$0.74	$0.35	$0.09	$0.33	$0.40	($12.98)	$0.05	$0.12
Adjusted Weighted Average Basic Shares Outstanding	90.95M	91.36M	91.63M	91.72M	91.62M	91.65M	90.33M	90.41M	90.71M	90.53M	90.82M
Adjusted Diluted Earnings per Share	$0.64	$0.83	$0.85	$0.74	$0.36	$0.09	$0.33	$0.40	($12.98)	$0.05	$0.12
Adjusted Weighted Average Diluted Shares Outstanding	90.95M	92.01M	92.04M	92.19M	92.06M	92.04M	90.44M	90.58M	90.71M	90.86M	91.37M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	92.29M	92.77M	92.87M	92.89M	92.91M	92.12M	92.35M	92.26M	92.21M	0.00	93.10M
Normalized Net Operating Profit after Tax (NOPAT)	100	103	108	107	86	53	108	115	-671	59	49
Normalized NOPAT Margin	13.45%	13.37%	13.61%	13.07%	11.13%	6.86%	12.42%	13.45%	-81.70%	7.08%	5.65%
Pre Tax Income Margin	10.77%	12.87%	13.37%	12.08%	4.91%	1.75%	5.75%	4.70%	-142.36%	1.32%	2.54%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	4.63	4.65	4.29	2.26	1.46	2.42	2.09	-28.84	1.29	1.58
NOPAT to Interest Expense	0.00	3.69	3.53	3.11	2.00	0.98	1.84	2.00	-20.19	0.52	0.88
EBIT Less CapEx to Interest Expense	0.00	-0.27	-0.60	-2.06	-4.50	-4.52	-1.88	-1.45	-31.20	-0.28	0.83
NOPAT Less CapEx to Interest Expense	0.00	-1.21	-1.72	-3.25	-4.76	-5.00	-2.46	-1.54	-22.55	-1.05	0.13
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-32.61%	-177.65%	121.08%	1.58%	1.12%	1.00%	2.28%	3.26%	-0.36%	-0.35%	-0.40%
Augmented Payout Ratio	-315.70%	-177.65%	123.67%	1.57%	1.12%	26.06%	37.67%	48.69%	-4.94%	-0.71%	-0.41%

Financials Breakdown Chart

Key Financial Trends

Acadia Healthcare (NASDAQ: ACHC) has shown a sharp rebound in early 2026, but the longer-term picture remains mixed. Q1 2026 revenue held near recent levels, profitability improved versus the prior quarter, and operating cash flow turned positive again. At the same time, the balance sheet still reflects a meaningful debt load, and the company continues to carry restructuring and special charges that have weighed on results over the last year.

Top takeaways from the last several quarters:

Q1 2026 revenue was $828.8 million, slightly above Q4 2025 and above the year-ago Q1 2025 level.
Operating income improved to $49.3 million in Q1 2026 from a large loss in Q4 2025, showing a strong sequential recovery.
Net income attributable to common shareholders was $4.1 million in Q1 2026, versus a steep loss in Q4 2025.
Operating cash flow turned positive again at $61.5 million in Q1 2026, a major improvement from the negative operating cash flow seen in late 2025.
Cash and equivalents rose to $158.5 million at the end of Q1 2026 from $118.7 million at the end of Q3 2025.
The company reduced long-term debt to $2.49 billion in Q1 2026 from $2.28 billion at Q3 2025 and $2.49 billion at Q4 2025, though leverage remains high overall.
Gross margin in Q1 2026 remained solid, with gross profit of $361.8 million on $828.8 million of revenue.
Selling, general and administrative expense increased again in Q1 2026 versus Q1 2025, which suggests cost control remains an important issue.
The company continued to record restructuring and special charges in recent quarters, signaling ongoing operational cleanup.
Q4 2025 was very weak, with a net loss of $1.18 billion driven by substantial special charges and a sharp drop in operating income.
Retained earnings remain negative at Q1 2026, reflecting the cumulative impact of prior losses and charges.
Debt remains elevated relative to equity, and interest expense continues to consume a meaningful portion of operating profit.

Revenue trend: ACHC has been able to keep quarterly revenue generally stable in a fairly tight range. Revenue was $704.3 million in Q1 2023, climbed to $815.6 million in Q3 2024, and reached $828.8 million in Q1 2026. That suggests the top line is growing, but not explosively. For a healthcare services company, steady revenue is helpful, but investors will likely care more about whether margins can hold and whether special charges keep fading.

Profitability trend: The company’s operating performance has been volatile. In 2024, ACHC generated healthy operating income in several quarters, including $126.1 million in Q1 2024 and $135.6 million in Q2 2025. But Q4 2025 stood out as a major setback, with operating income collapsing to a loss of $1.13 billion. In Q1 2026, operating income rebounded to $49.3 million, which is a much better sign, though still below the stronger quarters seen earlier in the cycle.

Bottom line: Acadia Healthcare appears to be in recovery mode after a difficult end to 2025. The early 2026 quarter showed improving earnings and positive operating cash flow, which are both encouraging. However, the company still carries a heavy debt burden and a history of large special charges, so investors will want to see several more quarters of consistent profitability before calling the turnaround complete.

08/15/26 04:35 PM ETAI Generated. May Contain Errors.

Acadia Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Acadia Healthcare's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Acadia Healthcare's net income appears to be on an upward trend, with a most recent value of -$1.09 billion in 2025, falling from $111.48 million in 2015. The previous period was $264.48 million in 2024. Check out Acadia Healthcare's forecast to explore projected trends and price targets.

Acadia Healthcare's total operating income in 2025 was -$925.81 million, based on the following breakdown:

Total Gross Profit: $1.49 billion
Total Operating Expenses: $2.42 billion

Over the last 10 years, Acadia Healthcare's total revenue changed from $1.83 billion in 2015 to $3.31 billion in 2025, a change of 81.1%.

Acadia Healthcare's total liabilities were at $3.39 billion at the end of 2025, a 22.4% increase from 2024, and a 30.9% increase since 2015.

In the past 10 years, Acadia Healthcare's cash and equivalents has ranged from $11.22 million in 2015 to $378.70 million in 2020, and is currently $133.24 million as of their latest financial filing in 2025.

Over the last 10 years, Acadia Healthcare's book value per share changed from 23.48 in 2015 to 21.13 in 2025, a change of -10.0%.

Related Companies

Financial statements for NASDAQ:ACHC last updated on 7/28/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acadia Healthcare (ACHC) Financials

Financials Breakdown Chart

Key Financial Trends

Acadia Healthcare Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acadia Healthcare (ACHC) Financials

Annual Income Statements for Acadia Healthcare

Quarterly Income Statements for Acadia Healthcare

Annual Cash Flow Statements for Acadia Healthcare

Quarterly Cash Flow Statements for Acadia Healthcare

Annual Balance Sheets for Acadia Healthcare

Quarterly Balance Sheets for Acadia Healthcare

Annual Metrics And Ratios for Acadia Healthcare

Quarterly Metrics And Ratios for Acadia Healthcare

Financials Breakdown Chart

Key Financial Trends

Acadia Healthcare Financials - Frequently Asked Questions

When does Acadia Healthcare's financial year end?

How has Acadia Healthcare's net income changed over the last 10 years?

What is Acadia Healthcare's operating income?

How has Acadia Healthcare's revenue changed over the last 10 years?

How much debt does Acadia Healthcare have?

How much cash does Acadia Healthcare have?

How has Acadia Healthcare's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools